• Explore /
  • Poster
  • / Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first‑line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first‑line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Abstract Poster

Authors

Rui-Hua Xu

Rui-hua Xu

Sun Yat-sen University Cancer Center, Guangzhou, China

Rui-hua Xu , Hendrik-Tobias Arkenau , Yung-Jue Bang , Crystal S. Denlinger , Ken Kato , Josep Tabernero , Jin Wang , Jiang Li , Henry Castro , Markus H. Moehler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Prevention, Screening, and Hereditary Cancers

Clinical Trial Registration Number

NCT03777657

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr TPS458)

Abstract #

TPS458

Poster Bd #

L2

Abstract Disclosures

Similar Posters

First Author: Josep Tabernero

First Author: Hendrik-Tobias Arkenau

First Author: Harry H. Yoon

First Author: Jian-Ming Xu